Serious infection due to strains of Pseudomonas aeruginosa that exhibit resistance to all common antipseudomonal antimicrobials increasingly is a serious problem. Colistin was used as salvage therapy for 23 critically ill patients with multidrug-resistant P. aeruginosa infection. Twenty-two patients who had septic shock ( ) and/or renal failure ( ) received mechanical ventilatory support at baseline. The most common n p 14 n p 21 types of infection were pneumonia ( ) and intra-abdominal infection ( ). Colistin was administered n p 18 n p 5 for a median of 17 days (range, 7-36 days). Seven patients died during therapy, at a median of 17 days (range, 4-26 days) after initiation of treatment. A favorable clinical response was observed in 14 patients (61%); only 3 patients experienced relapse. Bacteremia was the only significant factor associated with treatment failure ( ). One patient manifested diffuse weakness that resolved after temporary cessation of colistin therapy. P p .02 Colistin provides an important salvage therapeutic option for patients with otherwise untreatable serious P. aeruginosa infection.
Pseudomonas aeruginosa is the gram-negative pathogen that most commonly causes nosocomial pneumonia and is associated with the highest rates of crude and attributable mortality, even among patients who receive appropriate antimicrobial therapy [1] [2] [3] [4] [5] [6] . Strains of P. aeruginosa that have multiple intrinsic and acquired resistance mechanisms have become more prevalent at many tertiary care and academic medical centers [7, 8] .
The dominant resistance mechanisms include chromosomal-mediated hyperproduction of b-lactamase, loss of the specific outer membrane porin OprD, DNA gyrase mutations and efflux pumps, and plasmidmediated aminoglycoside-modifying enzymes, which confer resistance to antipseudomonal b-lactams, carba-penems, ciprofloxacin, and aminoglycosides, respectively [9] [10] [11] [12] [13] . The net effect of overlapping resistance mechanisms is a drastic reduction in the number of therapeutic options for serious P. aeruginosa infection. Moreover, highly resistant strains tend to be found in critically ill patients with significant comorbidities, prolonged hospitalization, and protracted exposure to antimicrobial selective pressures [14, 15] . Recently, the use of systemic colistin (polymyxin E), a cationic peptide with bactericidal activity against P. aeruginosa and many other gram-negative species, has shown efficacy against multidrug-resistant P. aeruginosa and Acinetobacter species [16, 17] . We report our experience with the use of parenteral colistin during a 7-year period to treat intensive care unit patients with infection due to panresistant or minimally susceptible P. aeruginosa strains.
METHODS

Patient population. All patients attended a 24-bed abdominal organ transplantation intensive care unit at
Downloaded from https://academic.oup.com/cid/article-abstract/37/11/e154/374036 by guest on 24 January 2019 the University of Pittsburgh Medical Center during the period of January 1996 through February 2003. The patient population included liver, kidney, pancreas, intestinal, and multivisceral organ recipients, as well as some nontransplant general surgery patients. Patients with panresistant or minimally susceptible P. aeruginosa isolates (isolates that were susceptible or intermediately susceptible only to aminoglycosides were considered to be minimally susceptible) were prospectively followed up from the day of initiation of colistin therapy to either discharge from the hospital or death. Patients were excluded if they received р3 days of colistin therapy. Routine clinical, laboratory, and microbiologic data were retrieved from a prospectively maintained computerized database (ParadoxII; Borland). Other database sources included the medical center's computerized microbiologic and pharmacologic archives. Additional collected data included age, sex, race, type and date of previous organ transplantation, duration of previous hospital and intensive care unit stay, septic shock, need for mechanical ventilatory or artificial renal support, liver failure, previous immunosuppression, and presence of other serious infections. Pharmacologic data included the dose and duration of colistin treatment and other antimicrobials administered within 4 weeks before the initiation of colistin and during colistin therapy. Microbiologic data included the type(s) of P. aeruginosa infection and the date of isolation and antimicrobial susceptibility of all P. aeruginosa isolates, including colistin susceptibility.
Microbiologic testing. Respiratory isolates were tested by disk diffusion methods with agar plate inocula of 10 5 organisms/mL and standard NCCLS zone size interpretative breakpoints [18] . All blood isolates had MIC determinations made by microbroth dilution techniques; titers at which no visible growth could be seen were recorded as MICs [18] . All P. aeruginosa isolates were tested for susceptibility to piperacillin, ceftazidime, ciprofloxacin, gentamicin, tobramycin, amikacin, and imipenem-cilastatin. Cefipime and meropenem testing was limited to the last 4 and 2 years of the study period, respectively. Macrobroth dilution testing for colistin susceptibility was performed when it was requested by the treating physician(s). Isolates were considered to be susceptible to colistin if the MIC was р2 mg/mL [19] .
Colistin administration. Initial colistin doses were selected on the basis of ideal body weight and estimated creatinine clearance [20] . All patients required dose adjustment for diminished or absent renal function on the first day of therapy. Patients with moderate renal dysfunction (serum creatinine level of 1.6-2.5 mg/dL) received 5.0 mg/kg/day divided into 2 doses administered at 12-h intervals; patients with severe renal dysfunction (serum creatinine level of 2.6-4.0 mg/dL) received 2.5 mg/kg/day as a single dose; patients with serum creatinine levels 14.0 mg/dL or who were undergoing hemodialysis received 1.0 mg/kg/day as a single dose. Drug was administered through a central or peripheral venous route in all cases. The treatment duration was determined by the primary treating physician(s), principally on the basis of clinical signs and symptoms of P. aeruginosa infection seen during follow-up.
Study definitions. Pneumonia was defined by the presence of fever/hypothermia or septic shock and of leukocytosis or left shift and unexplained pulmonary infiltrates, with isolation of P. aeruginosa either from an endotracheal/tracheostomy aspirate or from a bronchoscopic lavage specimen at a level of у10 4 organisms/mL. Septic shock was defined by a requirement for vasoactive pressors to maintain a systolic blood pressure 190 mm Hg. Renal failure was defined by a requirement either for intermittent hemodialysis or for continuous venovenous hemofiltration. Liver failure was defined by a bilirubin level 110 mg/dL and a prothrombin time 120 s without the presence of any other cause of coagulopathy. A "favorable response" was defined as complete or partial resolution of presenting symptoms and signs by the end of treatment, and an "unfavorable response" was defined as persistence or worsening of presenting symptoms and signs or death occurring during treatment.
Statistical analysis. Comparison of patients with favorable and unfavorable responses to treatment was performed using Fisher's exact test for categorical variables and Student's t test for continuous variables. A 2-tailed P value !.05 was considered to be statistically significant. All statistical analyses were performed with Minitab statistical software (release 13.31).
RESULTS
A total of 26 patients received parenteral colistin for the treatment of multidrug-resistant P. aeruginosa infection during the study period. Three patients were excluded because they received an inadequate course of therapy; thus, 23 patients were included in the study. The demographic and clinical features of the study cohort are summarized in table 1. Twenty patients (87%) had previously received abdominal solid-organ transplants and were undergoing iatrogenic immunosuppression, and the remaining 3 patients (13%) were recovering from general abdominal surgery. All patients were residing in the intensive care unit on the day that colistin therapy was initiated, and 16 patients (70%) remained in the intensive care unit for systems, 8 had failure of 3 organ systems, and 6 had failure of 4 organ systems. Types of infection with P. aeruginosa and other infecting organisms. Pneumonia was the most frequent primary type of P. aeruginosa infection, followed by intra-abdominal infection (table 2) . Five patients had documented P. aeruginosa infection of 2 types: 3 of these 5 patients had pneumonia and intra-abdominal infection, and 2 had pneumonia and wound infection. Pneumonia was diagnosed by quantitative cultures of bronchoscopic lavage specimens in 16 of 18 cases. Bilateral radiographic lung involvement was present in 15 patients, and single or multiple cavitary lesions were observed in 6 patients. One patient had unilateral empyema. P. aeruginosa bacteremia was present within 5 days before the initiation of colistin therapy in 8 patients. One patient had prosthetic aortic valve endocarditis with protracted P. aeruginosa bacteremia. Eleven patients had concurrent infection with у1 nonpseudomonal organism.
Baseline in vitro testing. Colistin susceptibility was determined in isolates obtained from 16 patients before the initiation of colistin therapy. All isolates were found by macrobroth dilution testing to be susceptible to colistin (MIC 90 of 2 mg/mL; figure 1 ). There was uniform resistance to all tested antipseudomonal b-lactams (piperacillin, ceftazidime, cefipime, and aztreonam), imipenem-cilastatin, ciprofloxacin, gentamicin, and tobramycin. Seven of 24 baseline isolates were susceptible to amikacin, and another 5 exhibited intermediate susceptibility to amikacin.
Colistin therapy and adjunctive treatment. The duration of colistin therapy ranged from 7 to 36 days (median, 17 days). Ten patients received colistin monotherapy, and 13 patients also received amikacin or an antipseudomonal b-lactam agent. Concurrent amikacin was used to treat 4 patients (2 with amikacinsusceptible strains and 2 with amikacin-intermediate strains). Antipseudomonal b-lactams directed at coinfecting enteric pathogens were also administered to 9 patients. One patient underwent thoracoscopic drainage of an empyema, and 4 patients underwent exploratory laparotomy and/or percutaneous drainage for the removal of infected intra-abdominal collections.
Clinical and microbiologic outcome. The parameters we used to measure therapeutic outcome are summarized in table 3. A favorable clinical outcome was observed in 14 patients with 16 types of infection (pneumonia in 10 patients, intraabdominal infection in 5, and wound infection in 1). Three of 14 patients who had a favorable response to treatment experienced relapses and were successfully treated with a second course of colistin. Follow-up microbiologic data from samples from the primary type of infection showed eradication of P. aeruginosa at the end of treatment in only 6 cases of pneumonia and 4 cases of intra-abdominal infection. A 2-log decrease in the P. aeruginosa load in follow-up quantitative cultures of bronchoscopic specimens was documented in 4 of 7 patients with favorable therapeutic responses. An unfavorable response was observed in 9 patients. There was no difference in response rates between the 10 patients who received colistin monother- , by 2-tailed P p .02 Fisher's exact test).
Colistin resistance was not observed during the follow-up period. Repeat P. aeruginosa isolates were obtained from 3 patients during colistin therapy and were tested for susceptibility to colistin. One exhibited a 1-fold increase in dilution (from 0.5 to 1.0 mg/mL) from the baseline MIC. One patient developed diffuse muscular weakness on day 10 of colistin treatment that resolved within 1 week after discontinuation of the colistin regimen. Twenty-one patients were already receiving artificial kidney support when colistin therapy was initiated. De novo renal failure requiring artificial kidney support occurred in 1 of the 2 other patients during colistin treatment. Superinfection with gram-negative organisms occurred in 3 patients during the colistin treatment period; Serratia marcescens bacteremia was found in 1 patient on day 12 of colistin, and 2 other patients developed Stenotrophomonas maltophilia pneumonia during the latter part of colistin therapy.
DISCUSSION
Our study is the largest report, to our knowledge, of systemic colistin treatment of P. aeruginosa infection in the modern antibiotic era. We believe the data demonstrate that salvage therapy with systemic colistin provided a moderate degree of efficacy against multidrug-resistant P. aeruginosa, despite a high degree of illness severity in a population of predominantly immunocompromised solid-organ transplant recipients. All patients with pneumonia in the study cohort met the American Thoracic Society definition for severe hospital-acquired pneumonia [21] . Parenteral colistin was administered as salvage therapy when most or all other antimicrobial options were exhausted. Although 12 P. aeruginosa isolates still retained full or intermediate susceptibility to amikacin, aminoglycoside monotherapy has been reported to have questionable efficacy for serious P. aeruginosa infection because of poor lung penetration, attenuated activity in abscesses, and the emergence of resistance [22, 23] .
The 61% favorable response rate and 61% in-hospital mortality rate were well within the broad reported range of clinical response and mortality rates for serious P. aeruginosa infection [3] [4] [5] [6] . The primary outcome parameter for nosocomial pneumonia in our study was the clinical response of the patient, rather than the results of microbiologic testing. Indeed, persistence of P. aeruginosa at a respiratory site was found in 7 of the 10 patients with favorable responses who had pneumonia, although a 2-log reduction in the quantity of P. aeruginosa was documented in 4 of 7 patients who had favorable responses for whom follow-up quantitative cultures of bronchoscopic specimens were performed. The partial disassociation of the clinical and microbiologic responses is, in part, a reflection of persistent artificial and native airway colonization with P. aeruginosa or- ganisms and is the reason that clinical outcome is the most relevant primary outcome parameter in evaluating therapeutic response in patients with ventilator-associated pneumonia [24, 25] . Our results are comparable to those of a series by Levin et al. [16] that reported a 56% favorable response rate to colistin therapy for both multidrug-resistant P. aeruginosa and Acinetobacter baumanii infection. Notably, the 25% pneumonia response rate observed in the study by Levin et al. was significantly lower than the response rate we observed in our cohort; however, their series included patients with Acinetobacter infection. P. aeruginosa bacteremia was the only variable significantly associated with an unfavorable response to colistin treatment. This finding is consistent with previous studies that have shown higher mortality rates among patients with bacteremic nosocomial pneumonia than among nonbacteremic patients [26, 27] . Another study that examined colistin treatment of P. aeruginosa bacteremia reported the development of endovascular sequelae during therapy [28] . One patient in our series who had P. aeruginosa bacteremia had prosthetic aortic valvular endocarditis. Successful treatment of pseudomonal endocarditis has been reported using the combination of colistin and trimethoprim-sulfamethoxazole and of polymyxin B with carbenicillin [29, 30] . Although colistin is bactericidal against P. aeruginosa, its ability to penetrate valvular vegetations and exert bactericidal activity against the high bacterial inoculum characteristic of endocarditic lesions is unknown.
Colistin has no activity against Proteus, Serratia, Providencia, and Edwardsiella species, Burkholderia cepacia, some strains of S. maltophilia, and the gram-negative cocci [31] . Despite this spectrum of organisms against which colistin does not provide coverage, breakthrough superinfections with colistin-resistant organisms (S. marcescens or S. maltophilia) were seen in only 3 patients. These organisms were susceptible to other antimicrobials. The susceptibility breakpoint for colistin as measured by broth dilution methods has not been established by current NCCLS guidelines. Disk diffusion methods are not recommended because of technical difficulties with the agar diffusion of colistin. Broth dilution titers of р2 mg/mL are generally accepted as a provisional susceptibility breakpoint [19] . Using this definition, colistin-resistant P. aeruginosa was not observed in our study, either at baseline or during follow-up. Colistin resistance among P. aeruginosa strains remains rare but has been described by others during aerosolized and systemic administration [32, 33] . The mechanism that leads to colistin resistance appears to be alterations in the cell-membrane lipid and cation structure [34] [35] [36] . Although we did not observe colistin resistance in our study, the use of monotherapy to treat P. aeruginosa infection has been identified as a risk factor for the development of on-therapy resistance [37] [38] [39] . Thus, the use of multiple broth dilution susceptibility tests appears to be prudent for patients who are receiving colistin monotherapy, so that resistance can be detected in patients who have a poor clinical response. Timekilling studies have shown synergism when colistin was combined with either b-lactams, ciprofloxacin, or rifampin against multidrug-resistant strains of P. aeruginosa. The clinical benefits of combination regimens in promoting efficacy and/or decreasing resistance remain unestablished [40, 41] .
Both systemic colistin and polymyxin B have been widely reported to cause both reversible nephrotoxicity and reversible neurotoxicity [42] . The advanced degree of critical illness present at baseline in our patient population is an important limitation that could obscure the detection of new colistin-related toxicities. All but 2 of our 23 patients already had established renal failure before the initiation of colistin therapy. Although the detection of colistin-associated nephrotoxicity is hampered by this background, it is conceivable that colistin may prolong the duration of a patient's need for artificial support in survivors who have established acute renal failure at the onset of therapy. Neurotoxicity resulting from colistin may include deficits in motor skills and sensory skills and coordination, as well as seizures and mental status changes, and neurotoxity has been reported to occur more frequently among patients with renal failure [43, 44] . Reversible neurotoxicity related to colistin was suspected in 1 patient in the present study; however, colistinrelated weakness may be difficult to discern in critically ill patients and in patients who are receiving parenteral sedatives and neuromuscular relaxants.
The development of better-tolerated antipseudomonal agents since the 1970s has largely contributed to the diminished use of systemic colistin. Thus, colistin has been relegated to nonsystemic applications that minimize its toxic potential and exploit its antibacterial properties. These include topical ophthalmic and otic preparations, combined oral and topical applications for selective bowel decontamination, and pulmonary aerosolization to abort progression to P. aeruginosa pneumonia in patients with cystic fibrosis. The resurrection of systemic colistin, an antiquated and toxic antimicrobial agent, for salvage therapy for serious P. aeruginosa infection is a sobering signal to the medical community. The evolution of resistance mechanisms, coupled with the lack of commercially available or investigational antipseudomonal compounds, has brought about this dangerous therapeutic void. Given this perspective, the moderate efficacy of colistin, despite toxicity concerns, magnifies its potential value as a therapy of last resort.
